Background: Coronavirus Disease 2019 (COVID-19) is a pandemic affecting all countries in the world. Italy has been particularly afflicted by the health emergency, and since the peak phase has passed, major concern regarding medium to long term complications due to COVID-19 is arising. Little is known in literature regarding thromboembolic complications once healed after COVID-19. Case presentation: A 51-year-old patient recovered from COVID-19 pneumonia complicated by pulmonary embolism (PE) came to the hospital for palpitations and chest pain. Although he was on treatment dose of direct oral anticoagulation (DOAC), massive recurrent PE was diagnosed. Conclusion: In the early post COVID-19 era, the question remains regarding the efficacy of DOACs in COVID-19 patients.

An unexpected case of recurrence of pulmonary embolism in a patient recovered from COVID19 in full regimen dose of direct oral anticoagulant drug / E. D'Elia, M. Gori, A. Grosu, A. Iorio, F.L. Lorini, A. Falanga, F. Di Marco, M. Senni. - In: BMC PULMONARY MEDICINE. - ISSN 1471-2466. - 21:1(2021), pp. 102.1-102.4. [10.1186/s12890-021-01453-2]

An unexpected case of recurrence of pulmonary embolism in a patient recovered from COVID19 in full regimen dose of direct oral anticoagulant drug

A. Falanga;F. Di Marco
Penultimo
;
2021

Abstract

Background: Coronavirus Disease 2019 (COVID-19) is a pandemic affecting all countries in the world. Italy has been particularly afflicted by the health emergency, and since the peak phase has passed, major concern regarding medium to long term complications due to COVID-19 is arising. Little is known in literature regarding thromboembolic complications once healed after COVID-19. Case presentation: A 51-year-old patient recovered from COVID-19 pneumonia complicated by pulmonary embolism (PE) came to the hospital for palpitations and chest pain. Although he was on treatment dose of direct oral anticoagulation (DOAC), massive recurrent PE was diagnosed. Conclusion: In the early post COVID-19 era, the question remains regarding the efficacy of DOACs in COVID-19 patients.
Case Report; Complications; COVID-19; Direct Oral Anticoagulation; Pulmonary Embolism; Administration, Oral; Anticoagulants; COVID-19; Dabigatran; Drug Therapy, Combination; Heparin; Humans; Male; Middle Aged; Pulmonary Embolism; Recurrence; Warfarin
Settore MED/10 - Malattie dell'Apparato Respiratorio
Article (author)
File in questo prodotto:
File Dimensione Formato  
2021 BMC PM Case rep TEP Delia.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 881.16 kB
Formato Adobe PDF
881.16 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/859144
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact